Cross-Sector entity
AtriCure is most often covered alongside Avance Nerve Graft, which appears in 2 of these 4 stories. Across a 33-day span, the pace is roughly 0.8 stories per week. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 4, with the remainder spread across 2 other categories.
4 verified stories tracked
Last mentioned: Mar 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
AtriCure is most often covered alongside Avance Nerve Graft, which appears in 2 of these 4 stories. Across a 33-day span, the pace is roughly 0.8 stories per week. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 4, with the remainder spread across 2 other categories. The tracked stories average 4 original sources each. This profile follows 4 Cross-Sector stories mentioning AtriCure across the period from February 18, 2026 to March 22, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AtriCure. Shared-story counts are live from our verified record — not editorial picks.
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, following a period of significant outperformance. Despite the trim, Axogen remains a core holding for the fund as the medical device maker continues to capitalize on its 20% revenue growth and dominant position in the peripheral nerve repair market.
Source: fool.com · Jonathan Ponciano (us)
A diverse group of mid-to-large cap companies across mining, energy, and healthcare reported stronger-than-expected quarterly results, signaling robust operational efficiency. IAMGOLD and EQT Corporation headlined the session with significant revenue outperformance, reflecting strength in commodity and energy markets.
Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Source: Seeking Alpha · Seeking Alpha
